Schedule of Revenue from Collaborations and Services (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services		$ 11,992	$ 17,436
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services		2,166	9,337
Collaborations and services | License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	[1]	1,348	8,999
Collaborations and services | Commercial Supply Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	[2]	694
Collaborations and services | License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services		37	36
Collaborations and services | Other
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services		$ 87
Collaborations and services | Co-Promotion Agreement | Vertice Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services			292
Collaborations and services | Collaboration and License Agreement | Receptor CLA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services			$ 10

[1] Amounts consist of revenue recognized for Next-Gen R&D Services for the three months ended March 31, 2022 and R&D Services and License for the three months ended March 31, 2021

[2] Amount consists of revenue recognized for Manufacturing Services for the three months ended March 31, 2022